Full-Time

Clinical Program Manager

Revolution Medicines

Revolution Medicines

1,001-5,000 employees

Clinical-stage oncology company developing RAS inhibitors

Compensation Overview

$143k - $178k/yr

San Carlos, CA, USA

Hybrid

Hybrid role; on-site at Redwood City, CA HQ with ~25% travel.

Bachelor's, Master's

Category
Business & Strategy (1)
Required Skills
FDA Regulations
Risk Management
Data Analysis
Google Cloud Platform

Get referred to Revolution Medicines

See people who can refer or advise you

Requirements
  • RN or Bachelor’s or Masters degree in biological sciences or health-related field required
  • 8+ years direct Clinical Operations experience in the pharmaceutical or biotech industry, preferably in Clinical Operations or Clinical Research-related experience. Relevant indirect experiences may also meet the requirement
  • Minimum of 4 years of cross-functional study management or related leadership experience in life sciences, including multiple years’ experience managing project teams
  • Strong working knowledge of FDA Regulations, ICH Guidelines, and GCP
  • Proven ability to successfully start-up, manage, and close-out clinical trials, including authoring clinical study and regulatory documentation and SOPs
  • Experience in selection of CROs/vendors and management of external resources
  • Thrive in a collaborative team setting that demonstrates flexibility required to maintain a fast pace and is driven by a desire to deploy innovative approaches and technologies in a high-energy environment
  • Be solution-oriented by anticipating obstacles and difficulties, and proactively providing risk assessment and mitigation strategies to achieve project goals
  • Excellent written/verbal communication and interpersonal skills
  • High sense of priority and commitment to excellence in the successful execution of deliverables
  • Ability to analyze operational data, contribute with a mind on quality, timeliness and fiscal responsibility, make and drive decisions, multi-task, prioritize tasks, anticipate challenges, and execute on goals as a member of an interdisciplinary team
  • Demonstrate proficiency in Microsoft Office Suite (Outlook, MS Word, Excel, PowerPoint); MS Project and/or Smartsheet a plus
  • Travel may be required (~25%)
Responsibilities
  • Adhere to Clinical Standard Operating Procedures (SOP), Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) Guidelines
  • Be a team leader, providing guidance and oversight for the successful management of all aspects of clinical trials within timelines and designated program budgets
  • Partner with cross-functional teams to manage, adjust, and revise project timelines and budgets as needed
  • Analyze data health metrics to be shared with stakeholders
  • Actively partner with cross-functional teams and vendors to drive the query resolution and data listings review process to meet objectives in a timely and efficient process
  • Conduct risk management, contingency, and scenario planning
  • Supervise, communicate project status/issues, and problem solve to ensure project team goals are met
  • Participate in the development of all study-related documentation, including study protocols
  • Actively contributes in the selection and management of contract research organizations (CROs) and/or vendors, including development of requests for proposals (RFPs)
  • Use all available tools to track, oversee, and communicate on program status to all key stakeholders
  • Participate in other Clinical Operations activities as appropriate
  • Leads a larger, more complex trial with some oversight from senior members of Clinical Operations
  • With minimal support, lead cross-functional Clinical Study Execution Team (CSETs)
  • Participate in and contribute to SOP development, implementation, and training
  • Support junior team members through mentorship
Desired Qualifications
  • Familiarity working with vendor systems/portals (e.g., eTMF, EDC, IRT, CTMS)
  • Oncology experience, early and/or late stage, strongly preferred
  • Knowledge and/or familiarity with Ex-US region(s) clinical trial operations
  • Some experience mentoring junior staff

Revolution Medicines develops targeted therapies for cancers caused by RAS mutations, which are found in about 30% of human cancers. The company’s products are small molecules called RAS(ON) inhibitors that work by blocking the active, cancer-promoting form of the RAS protein to stop tumor growth. Unlike older treatments that could only target a few specific mutations, this platform creates inhibitors that can address a much wider range of RAS-driven cancers. The company's goal is to advance these candidates through clinical trials to provide effective treatment options for patients with previously "undruggable" forms of cancer.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Redwood City, California

Founded

2014

Get referred to Revolution Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA accepted daraxonrasib NDA July 22, 2026, accelerating first commercial launch.
  • BeOne will fund a global Phase 3, reducing Revolution's late-stage cash burden.
  • Cash and marketable securities reached $3.9 billion on June 30, 2026, funding operations.

What critics are saying

  • Daraxonrasib still depends on FDA approval after the August 2026 NDA acceptance.
  • R&D burned $394.9 million in Q2 2026; cumulative losses reached $4.0 billion.
  • If daraxonrasib disappoints in pancreatic launch or NSCLC readouts, Revolution loses its value anchor.

What makes Revolution Medicines unique

  • Daraxonrasib delivered 13.2-month median OS in RASolute 302, versus 6.7 months chemotherapy.
  • Revolution Medicines targets active RAS with RAS(ON) inhibitors across KRAS G12C, G12D, and G12V.
  • The BeOne August 2026 deal validates its platform and extends regional commercialization reach.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-3%

2 year growth

-4%
Yahoo Finance
Aug 13th, 2026
Revolution Medicines shares rise 6.2% on BeOne-funded Phase 3 RAS(ON) deal

Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.

The Montreal Gazette
Aug 10th, 2026
BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration.

BeOne Medicines and Revolution Medicines announce clinical development and Regional commercialization collaboration. Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancers Regional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets SAN CARLOS, Calif. & REDWOOD CITY, Calif. - BeOne Medicines Ltd. (Nasdaq: ONC; HKEX:...

Associated Press
Aug 5th, 2026
Revolution Medicines files daraxonrasib NDA for pancreatic cancer, raises $2.2B

Revolution Medicines announced second quarter 2026 financial results, reporting cash and marketable securities of $3.9 billion as of 30 June. The company completed concurrent public offerings totalling $2.2 billion in gross proceeds and received $250 million from Royalty Pharma. The FDA accepted the company's new drug application for daraxonrasib to treat previously treated metastatic pancreatic cancer. Over 2,000 patients have received the drug through an expanded access programme since May. The FDA also granted breakthrough therapy designation for daraxonrasib in certain non-small cell lung cancer patients. Research and development expenses rose to $394.9 million from $224.1 million year-over-year, whilst general and administrative expenses increased to $110.2 million from $40.6 million. Net loss totalled $644.4 million, compared to $247.8 million in the prior year quarter.

TraderFox GmbH
Jul 28th, 2026
Revolution Medicines: the attack on the unbreakable cancer code.

Revolution Medicines: the attack on the unbreakable cancer code. Reading time: 3 minutes Revolution Medicines is developing novel active ingredients that specifically block the active form of cancer-driving RAS proteins, which were previously considered untreatable and are responsible for about a third of all cancers. With the advanced hopeful candidate Daraxonrasib, the company is filling a huge supply gap in difficult-to-treat tumors such as pancreatic and lung cancer. Thanks to strong capital partners, the transition from research to commercial provider is financially secured, nevertheless... Trader newspaper - order now for only 1 €. for 28 days Then 3 months duration Total price: 99,- € Price drop after China report: Technological advances of a state-funded Chinese competitor cause ASML to drop by 5.8%... July 27, 2026 could go down as a turning point in the history of quantum computing. Two pieces of news arrived simultaneously and fueled each other:...

Yahoo Finance
Jul 9th, 2026
Revolution Medicines soars 135% as phase 3 oncology results trump Axsome's 34% gain

Axsome Therapeutics and Revolution Medicines have delivered strong returns this year, with shares climbing 34% and 135% respectively in the first half. Both biotechnology companies attracted investors seeking growth opportunities beyond artificial intelligence. Axsome specialises in central nervous system disorders and has three marketed products. In the recent quarter, Auvelity sales rose 59% to $153 million, whilst Sunosi revenue increased 34% to $33 million. The company recently secured approval for Auvelity in treating Alzheimer's agitation and has five phase 3 programmes underway. Revolution Medicines, whilst earlier-stage with no commercialised products yet, has candidates in registrational trials for pancreatic cancer and non-small cell lung cancer treatment. The company recently announced positive phase 3 results for its lead oncology candidate.